Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 29.35% is 44% below its 5-year average of 52.58%, near the low end of its 5-year range (29.35%–58.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.13% below its 12-month average of 42.01%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 29.35%.
DEBT TO ASSETS RATIO
29.35%
DEBT TO ASSETS RATIO AVG TTM
42.01%
DEBT TO ASSETS RATIO AVG 3Y
54.39%
DEBT TO ASSETS RATIO AVG 5Y
52.58%
DEBT TO ASSETS RATIO AVG 10Y
45.10%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-30.13%
CURRENT VS 3Y AVG
-46.04%
CURRENT VS 5Y AVG
-44.18%
CURRENT VS 10Y AVG
-34.92%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 843 covered companies
CURRENT VS SECTOR MEDIAN
+32515.50%
vs the sector median at left
Novocure Ltd
Market Cap
$1.78B
Debt to Assets Ratio
29.35%
TTM Avg
42.01%
3Y Avg
54.39%
5Y Avg
52.58%
Market Cap
$1.76B
Debt to Assets Ratio
0.26%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.75B
Debt to Assets Ratio
0.50%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.80B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.75B
Debt to Assets Ratio
0.70%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.82B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novocure Ltd (NVCR) | $1.78B | 29.35% | 42.01% | 54.39% | 52.58% |
| Absci Corporation (ABSI)vs › | $1.78B | 0.01% | N/A | N/A | N/A |
| Novavax, Inc. (NVAX)vs › | $1.80B | 0.31% | N/A | N/A | N/A |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 0.26% | N/A | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 0.50% | N/A | N/A | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.80B | 0.11% | N/A | N/A | N/A |
| Xencor, Inc. (XNCR)vs › | $1.80B | 0.09% | N/A | N/A | N/A |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.75B | 0.70% | N/A | N/A | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 0.30% | N/A | N/A | N/A |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | 0.33% | N/A | N/A | N/A |
Debt/Assets
29.4%
Debt/Equity
0.69
Current Ratio
2.89
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 29.35% |
| 2026-03-31 | 29.82% |
| 2025-12-31 | 36.06% |
| 2025-09-30 | 58.62% |
| 2025-06-30 | 56.21% |
| 2025-03-31 | 55.79% |
| 2024-12-31 | 55.07% |
| 2024-09-30 | 55.29% |
| 2024-06-30 | 55.70% |
| 2024-03-31 | 53.08% |
| 2023-12-31 | 52.02% |
| 2023-09-30 | 51.47% |
| 2023-06-30 | 50.69% |
| 2023-03-31 | 49.93% |
| 2022-12-31 | 49.03% |
| 2022-09-30 | 49.35% |
| 2022-06-30 | 49.65% |
| 2022-03-31 | 50.24% |
| 2021-12-31 | 51.07% |
| 2021-09-30 | 51.13% |
| 2021-06-30 | 52.19% |
| 2021-03-31 | 53.60% |
| 2020-12-31 | 42.84% |
| 2020-09-30 | 3.03% |
| 2020-06-30 | 30.85% |
| 2020-03-31 | 32.39% |
| 2019-12-31 | 35.08% |
| 2019-09-30 | 36.22% |
| 2019-06-30 | 39.62% |
| 2019-03-31 | 43.30% |
| 2018-12-31 | 43.93% |
| 2018-09-30 | 47.30% |
| 2018-06-30 | 48.15% |
| 2018-03-31 | 49.15% |
| 2017-12-31 | 36.69% |
| 2017-09-30 | 37.00% |
| 2017-06-30 | 37.65% |
| 2017-03-31 | 36.46% |
| 2016-12-31 | 34.11% |
| 2016-09-30 | 32.97% |
| 2016-06-30 | 9.30% |
| 2016-03-31 | 8.31% |
| 2015-12-31 | 7.52% |
| 2015-09-30 | 14.13% |
| 2015-06-30 | 12.73% |
| 2015-03-31 | 20.63% |
| 2014-12-31 | 0.27% |
